Amneal Pharmaceuticals (AMRX) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Is BPMC or AMRX more profitable?

Amneal Pharmaceuticals has a net margin of -0.46% compared to Blueprint Medicines' net margin of -27.70%. Blueprint Medicines' return on equity of -64.60% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Amneal Pharmaceuticals	-0.46%	-188.26%	5.34%

Do insiders & institutionals believe in BPMC or AMRX?

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts rate BPMC or AMRX?

Blueprint Medicines currently has a consensus price target of $128.06, indicating a potential downside of 0.07%. Amneal Pharmaceuticals has a consensus price target of $11.60, indicating a potential upside of 42.68%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor BPMC or AMRX?

In the previous week, Blueprint Medicines had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Blueprint Medicines and 4 mentions for Amneal Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.94 beat Amneal Pharmaceuticals' score of 0.63 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, BPMC or AMRX?

Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Which has higher earnings and valuation, BPMC or AMRX?

Blueprint Medicines has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	16.26	-$67.09M	-$2.47	-51.88
Amneal Pharmaceuticals	$2.79B	0.91	-$116.89M	-$0.04	-203.25

Summary

Amneal Pharmaceuticals beats Blueprint Medicines on 10 of the 17 factors compared between the two stocks.